TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer | Zendy

Shanyu Guo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer

Author(s) -

Shanyu Guo

Publication year - 2003

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v9.i2.233

Subject(s) - suicide gene , transfection , genetic enhancement , cancer , viral vector , cancer research , thymidine kinase , in vivo , cancer cell , ganciclovir , microbiology and biotechnology , bystander effect , gene delivery , biology , medicine , immunology , gene , virus , human cytomegalovirus , biochemistry , herpes simplex virus , recombinant dna

Cancer gene therapy has received more and more attentions in the recent decade. Various systems of gene therapy for cancer have been developed. One of the most promising choices is the suicide gene. The product of thymidine kinase (TK) gene can convert ganciclovir (GCV) to phosphorylated GCV, which inhibits the synthesis of cell DNA, and then induces the cells to death. Cytokines play an important role in anti-tumor immunity. This experiment was designed to combine the TK gene and mIL-2/mGM-CSF genes to treat gastric cancer, and was expected to produce a marked anti-tumor effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research